Affimed Net Income 2014-2024 | AFMDQ
Affimed net income from 2014 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Affimed Annual Net Income
(Millions of US $) |
| 2023 |
$-115 |
| 2022 |
$-91 |
| 2021 |
$-68 |
| 2020 |
$-47 |
| 2019 |
$-36 |
| 2018 |
$-23 |
| 2017 |
$-34 |
| 2016 |
$-36 |
| 2015 |
$-22 |
| 2014 |
$0 |
| 2013 |
$-35 |
| 2012 |
$-18 |
Affimed Quarterly Net Income
(Millions of US $) |
| 2024-09-30 |
$-17 |
| 2024-06-30 |
$-17 |
| 2024-03-31 |
$-21 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-27 |
| 2023-06-30 |
$-32 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-35 |
| 2022-09-30 |
$-17 |
| 2022-06-30 |
$-21 |
| 2022-03-31 |
$-19 |
| 2021-12-31 |
$-27 |
| 2021-09-30 |
$-20 |
| 2021-06-30 |
$-23 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$-18 |
| 2020-09-30 |
$-7 |
| 2020-06-30 |
$-13 |
| 2020-03-31 |
$-9 |
| 2019-12-31 |
$-15 |
| 2019-09-30 |
$-12 |
| 2019-06-30 |
$-12 |
| 2019-03-31 |
$2 |
| 2018-12-31 |
$11 |
| 2018-09-30 |
$-14 |
| 2018-06-30 |
$-10 |
| 2018-03-31 |
$-10 |
| 2017-12-31 |
$-8 |
| 2017-09-30 |
$-10 |
| 2017-06-30 |
$-9 |
| 2017-03-31 |
$-8 |
| 2016-12-31 |
$-6 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-9 |
| 2015-12-31 |
$-7 |
| 2015-09-30 |
$-8 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-2 |
| 2014-12-31 |
$-6 |
| 2014-09-30 |
$9 |
| 2014-06-30 |
$18 |
| 2014-03-31 |
$-21 |
| 2013-09-30 |
$-15 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
